Blade Air Mobility Earnings Call Highlights Growth, Volatility

Blade Air Mobility, Inc. ((SRTA)) has held its Q1 earnings call. Read on for the main highlights of the call.

Blade Air Mobility, Inc. struck an upbeat tone on its latest earnings call, underscoring explosive year-over-year growth, expanding clinical operations and solid cash generation. Management acknowledged some short-term margin and logistics volatility but framed these as manageable, reiterating full-year guidance and stressing ample balance sheet capacity to keep investing and doing deals.

Revenue Growth

Total revenue jumped 87.4% year over year to $67.4 million in Q1 2026, outpacing guidance and edging about 1% higher sequentially. Management said adjusted EBITDA also came in ahead of expectations, reinforcing the view that the business is scaling quickly despite quarterly noise.

Strong Organic Logistics Growth

Organic Logistics revenue, excluding Keystone, climbed 32.4% from a year ago to $47.6 million, fueled by higher air revenues from both new and existing customers. This performance highlights the underlying strength of the company’s core transportation network even as quarterly mix shifts pressure margins.

Rapid Build-Out of Clinical Business

The Clinical segment, added via Keystone, delivered $19.8 million in Q1 revenue, up 12.7% from Q4 2025 as the business ramps. Transplant Clinical rose 26.7% sequentially and Other Clinical also grew, reflecting successful cross-sell efforts and onboarding of new hospital and transplant customers.

Profitability and Margins Improvement Year-over-Year

Gross profit doubled to $14.1 million compared with $7.1 million a year earlier, pushing the gross margin to 21.0% from 19.6%. Management credited the Keystone acquisition mix and operating leverage as key drivers, showing that scale is beginning to translate into better unit economics.

Clinical Margin Strength

Clinical gross profit increased 29.2% sequentially to $5.0 million, with segment gross margin improving to 25.0% from 21.8%. The uplift was driven by a greater mix of higher-margin transplant clinical services, although management cautioned that this margin level may not repeat every quarter.

Cash Generation and Balance Sheet Capacity

Operating cash flow reached $3.9 million in Q1 and free cash flow before aircraft and engine purchases was $2.1 million. With $58.8 million in cash and short-term investments, an undrawn $30 million asset-based facility and expected earn-outs, the company emphasized meaningful capacity to fund growth and acquisitions.

M&A Activity and Pipeline

The company closed the acquisition of Ohio Valley Perfusion Associates for roughly $1 million, expected to add about $100,000 of adjusted EBITDA in 2026. Management also highlighted an active deal pipeline spanning logistics, surgical recovery, placement and cardiac perfusion, with several opportunities already under exclusivity.

Fleet and Geographic Expansion

Blade added one aircraft in the quarter, bringing owned aircraft to 10 and a dedicated fleet of around 35, while capital expenditures totaled $5.5 million. It also opened several new aviation bases, expanded to roughly 20 logistics hubs and launched a combined Logistics and Clinical hub in Chicago to better cover the Midwest.

Industry Tailwinds and Market Position

Management pointed to rising adoption of normothermic regional perfusion in more than half of donation-after-circulatory-death donors and growing use of third-party surgical recovery. Sequential improvement in deceased donor volumes since Q4 2025 is also supporting demand for the company’s integrated clinical and logistics platform.

Sequential Logistics Softness and Margin Pressure

Despite strong annual growth, Logistics revenue declined 3.3% sequentially and Logistics gross margin slipped to 19.3%, down 30 basis points year over year and 220 basis points from Q4. The company cited a customer mix shift toward organ procurement organizations with shorter trip distances as the main driver of the compression.

Adjusted EBITDA and Margin Decline Sequentially

Adjusted EBITDA fell to $6.4 million in Q1 from $7.0 million in Q4 2025, with margin easing to 9.5%. Management attributed the decline to lower Logistics gross margins and a modest increase in adjusted SG&A, while emphasizing that profitability remains solid on a year-over-year basis.

One-Time and Timing Cash Headwinds

Operating cash flow trailed adjusted EBITDA by $2.5 million, reflecting about $1 million of non-cash income statement adjustments. A $1.5 million working capital increase from annual incentive compensation payments in Q1 and $3.7 million of aircraft spending within $5.5 million of capex weighed on near-term free cash flow.

Donor Volume Uncertainty

Deceased donor levels remain down versus last year, even though they have improved sequentially since Q4 2025. Management is not assuming a full recovery in donor volumes in its outlook, leaving some potential upside but also underscoring continued uncertainty in the core demand environment.

Weather and Operational Disruptions

Winter storms and airport closures, including a multi-day shutdown at Peterborough, reduced flights during the quarter. These disruptions added to the sequential softness in Logistics performance and illustrate the operational sensitivity of the network to severe weather.

Customer Mix Variability Risk

Management emphasized that quarter-to-quarter shifts in customer mix between organ procurement organizations and transplant centers, as well as changes in aircraft type and trip length, can materially influence Logistics margins. This variability limits short-term visibility into margin trends, even as long-term growth drivers remain intact.

Residual Transaction and Contingent Risks

The company noted that its expected earn-out from Joby is contingent and partially payable in stock, which is revalued quarterly and introduces some balance sheet volatility. In addition, the presence of a sizable warrant overhang near expiration carries the risk of future dilution or capital structure shifts.

Modest SG&A Increase

Adjusted SG&A rose modestly by $0.3 million sequentially to $9.2 million, reflecting investments in people and infrastructure. Management signaled that SG&A will likely grow further, but at a measured pace, to support new hubs and the scaling of both Logistics and Clinical operations.

Clinical Margin Sustainability Uncertainty

While the Clinical segment posted a strong 25% gross margin in Q1, the company cautioned that such levels may not be sustainable every quarter. Future margins will depend heavily on the mix between higher-margin transplant clinical services and other clinical offerings, which can shift over time.

Forward-Looking Guidance

Management reaffirmed its 2026 targets for revenue of $260 million to $275 million, adjusted EBITDA of $29 million to $33 million and free cash flow before aircraft and engine purchases of $15 million to $22 million. For Q2, revenue is expected to grow in the low single digits sequentially with an adjusted EBITDA margin of around 10%, while Logistics and Clinical margins are seen holding near current levels.

Blade Air Mobility’s call painted a picture of a company in rapid expansion mode, balancing impressive top-line growth and clinical momentum with some near-term margin and volume uncertainty. For investors, the key themes were confidence in the long-term trajectory, continued M&A optionality and a willingness to invest through short-term volatility to consolidate its position in a growing niche market.